Benefits
Antidepressant-like effects DOPAMINE-mediated (Campos 2005 PMID 16025317)
Campos MM, Fernandes ES, Ferreira J et al. 2005 (Psychopharmacology, doi:10.1007/s00213-005-0052-1, PMID 16025317) — assessed antidepressant-like effects of Trichilia catigua extract in rodents. In vivo (forced swimming test) + in vitro (monoamine reuptake + release in synaptosomal preparations). RESULTS: Acute oral T. catigua extract produced ANTIDEPRESSANT-LIKE EFFECTS in forced swimming model in BOTH MICE AND RATS. T. catigua extract concentration-dependently INHIBITED UPTAKE + INCREASED RELEASE of SEROTONIN, and ESPECIALLY of DOPAMINE, from rat brain synaptosomes. Significant DOPAMINE-MEDIATED mechanism evidence. PRECLINICAL — important caveat for human translation.
Antidepressant Catuama® combination (preclinical)
Catuama® (Brazilian herbal product) — combination of T. catigua + Paullinia cupana + Zingiber officinale + Ptychopetalum olacoides extracts. Pharmacological + neurochemical evidence supports antidepressant-like effects. PARTIAL VASCULAR RELAXATION via NO-mediated mechanism (1073 μg/mL EC50 in rat mesenteric artery rings). Multi-component synergy.
Antifatigue + memory effects (preclinical)
Pre-clinical studies: T. catigua extract demonstrates ANTIFATIGUE effects + PRO-MEMORY effects in rodent models. Hexane, chloroform, hydroalcoholic, aqueous extracts compared — HYDROALCOHOLIC EXTRACT most active for antifatigue properties. Anticholinesterase activity in vitro supports memory benefits. Foundational Brazilian traditional use mechanism evidence.
Antidepressant clinical trial RECRUITING (LABCAT TCJUSS NCT02532660)
NCT02532660 — Brazilian clinical trial recruiting. LABCAT TCJUSS in patients with DEPRESSIVE EPISODE. Important emerging clinical trial bringing Brazilian preclinical evidence to human depression context. Status pending but represents transition from preclinical to clinical research.
Aphrodisiac + sexual function (traditional + preclinical)
Traditional Brazilian medicine: T. catigua extensively used for IMPOTENCE + LIBIDO support. Brazilian ethnopharmacological literature compiled 74 plant species for sexual dysfunction — T. catigua among 14 with pharmacological studies confirming therapeutic properties. Probable mechanisms: antioxidant + androgenic + PDE5 inhibition + NO levels increase + dopaminergic/noradrenergic pathway activation. PRECLINICAL evidence; limited human clinical trials.
Anti-inflammatory + neuroprotective (preclinical)
Pre-clinical: T. catigua extracts have anti-inflammatory, antinociceptive, neuroprotective effects against ischemia and oxidative stress. Multiple mechanisms support broad CNS + systemic anti-inflammatory potential. Mechanism via flavalignans + flavonoids + proanthocyanidins polyphenol matrix.
Antioxidant capacity (multiple studies)
Antioxidant + anticholinesterase activity demonstrated in vitro (PMC5987406). Polyphenolic flavalignans + flavan-3-ols provide ROS scavenging. Mechanism: comprehensive antioxidant activity supporting cognitive + general health applications.
Mechanism of action
Dopamine reuptake inhibition + release increase (PRIMARY mechanism)
Campos 2005 demonstrated T. catigua extract concentration-dependently INHIBITS DOPAMINE UPTAKE + INCREASES DOPAMINE RELEASE from rat brain synaptosomes. Mechanism distinct from typical SSRI antidepressants (which target serotonin primarily). DOPAMINE FOCUS distinguishes T. catigua — important for depression with anhedonia/motivation deficits. Foundation antidepressant + libido + energy mechanism.
Serotonin reuptake inhibition (secondary)
Campos 2005 also demonstrated serotonin reuptake inhibition + release increase. Combined dopamine + serotonin mechanism. Less prominent than dopamine effect but contributes to broader mood/anxiety profile.
Anticholinesterase activity (memory mechanism)
PMC5987406 — anticholinesterase activity in vitro. Mechanism for pro-memory effects. Acetylcholine preservation supports cognitive function — relevant to traditional memory deficit use.
NO-mediated vascular relaxation
Catuama combination produces partial vascular relaxation antagonized by L-NOARG (NO synthase inhibitor). Mechanism: NITRIC OXIDE-MEDIATED smooth muscle relaxation. Important for sexual function + cardiovascular applications.
Antioxidant via polyphenol matrix
Flavalignans (cinchonain) + flavan-3-ols + proanthocyanidins provide comprehensive antioxidant activity. Mechanism for neuroprotective + general health effects.
PDE5 inhibition (sexual function mechanism, preclinical)
Probable mechanism for sexual function effects per ethnopharmacological review. Mechanism: similar to sildenafil but milder. Preclinical evidence; human translation limited.
Anti-inflammatory + antinociceptive
Multiple anti-inflammatory mechanisms in preclinical models. Pain modulation mechanisms. Broad CNS + peripheral applications.
Clinical trials
Preclinical pharmacology study (Campos MM, Fernandes ES, Ferreira J, Santos AR, Calixto JB 2005, Psychopharmacology, doi:10.1007/s00213-005-0052-1, PMID 16025317).
Mice + rats. Forced swimming test (in vivo) + monoamine reuptake/release in rat brain synaptosomal preparations (in vitro). Acute oral T. catigua hydroalcoholic extract.
ANTIDEPRESSANT-LIKE EFFECTS in forced swimming model in BOTH MICE AND RATS. CONCENTRATION-DEPENDENT INHIBITION of UPTAKE + INCREASED RELEASE of SEROTONIN and ESPECIALLY DOPAMINE from rat brain synaptosomes. Significant DOPAMINE-MEDIATED antidepressant mechanism evidence. Foundational preclinical pharmacology — but PRECLINICAL ONLY (mice + rats, not humans).
Multiple preclinical studies of Catuama® (Brazilian combination of T. catigua + Paullinia cupana + Zingiber officinale + Ptychopetalum olacoides).
Rodent models + in vitro studies. Combined herbal product evaluation.
Pharmacological + neurochemical evidence for ANTIDEPRESSANT-LIKE EFFECTS of Catuama®. PARTIAL VASCULAR RELAXATION via NO-mediated mechanism (1073 μg/mL EC50 in rat mesenteric artery rings). MULTI-COMPONENT SYNERGY. Foundational evidence for combined Brazilian herbal traditional use. PRECLINICAL — important caveat.
Brazilian clinical trial NCT02532660.
Patients with DEPRESSIVE EPISODE. LABCAT TCJUSS (Trichilia catigua) intervention.
STATUS: RECRUITING. Important emerging clinical trial bringing Brazilian preclinical evidence to human depression context. EXCLUSION: bleeding disorders, alcohol/drug addiction, pregnancy/lactation, hyperthyroidism, diabetes, suicide/violence risk, antidepressant/sedative use within 15 days. Will represent significant transition from preclinical to clinical research if completed.
About this ingredient
CATUABA refers to bark extracts of TRICHILIA CATIGUA A. Juss. (Meliaceae family) — Brazilian Amazon medicinal tree.
CRITICAL SPECIES NOTE: 'Catuaba' is common name applied to MULTIPLE SPECIES including Trichilia catigua (Big Catuaba — primary medicinal species), Erythroxylum catuaba (different plant family Erythroxylaceae, also called catuaba), Anemopaegma arvense, Heteropterys tomentosa, others — ADULTERATIONS lead to controversial effects. T. catigua is the most commonly used + most relevant species. Used in Brazilian traditional medicine for AGE-RELATED COGNITIVE DECLINE, DEPRESSION, ANXIETY, MALE SEXUAL DYSFUNCTION, fatigue, nerve pain. ACTIVE COMPOUNDS: FLAVALIGNANS (cinchonain Ia, Ib, IIa, IIb — most distinctive class), FLAVAN-3-OLS (catechin, epicatechin), PROANTHOCYANIDINS, ω-PHENYL ALKANES + alkanoic acids + γ-lactones, ALKYL-γ-LACTONES, ALKENYL-γ-LACTONES, β-SITOSTEROL, STIGMASTEROL, CAMPESTEROL, fatty acids. Hydroalcoholic extract most pharmacologically active per comparative studies. CLINICAL EVIDENCE — Note: HUMAN clinical trials LIMITED; primarily PRECLINICAL evidence. CAMPOS 2005 PMID 16025317 (Psychopharmacology, doi:10.1007/s00213-005-0052-1) FOUNDATIONAL preclinical mechanism — antidepressant-like effects in mice + rats forced swimming model + DOPAMINE-MEDIATED MECHANISM (concentration-dependent inhibition of dopamine uptake + increased release from rat brain synaptosomes; serotonin secondary). CATUAMA® COMBINATION studies (T. catigua + Paullinia cupana + Zingiber officinale + Ptychopetalum olacoides) — pharmacological + neurochemical evidence + NO-mediated vascular relaxation (1073 μg/mL EC50). PMC5987406 — antioxidant + anticholinesterase + antifatigue effects. ETHNOPHARMACOLOGICAL REVIEWS confirm 74 Brazilian plants for sexual dysfunction with T. catigua among 14 with pharmacological confirmation. NCT02532660 LABCAT TCJUSS Brazilian clinical trial RECRUITING in depressive episode patients — emerging clinical evidence.
MECHANISMS: DOPAMINE reuptake inhibition + release increase (PRIMARY mechanism — distinguishes from typical SSRI antidepressants); serotonin reuptake inhibition (secondary); ANTICHOLINESTERASE activity (memory mechanism); NO-MEDIATED vascular relaxation (sexual + cardiovascular applications); antioxidant via polyphenol matrix (flavalignans + flavan-3-ols + proanthocyanidins); PDE5 inhibition (preclinical sexual function mechanism); anti-inflammatory + antinociceptive. EVIDENCE: 2/5 reflects: (1) CAMPOS 2005 PIVOTAL preclinical mechanism characterization with significant dopamine-mediated antidepressant evidence, (2) MULTIPLE preclinical studies supporting traditional Brazilian use claims, (3) NCT02532660 emerging clinical trial RECRUITING, (4) WELL-CHARACTERIZED dopamine-focused mechanism distinct from typical SSRI antidepressants, (5) ETHNOPHARMACOLOGICAL evidence base from extensive Brazilian traditional use, (6) Catuama® combination synergistic evidence, (7) HUMAN CLINICAL TRIALS LIMITED — important honest framing limitation, (8) SPECIES IDENTIFICATION + ADULTERATION risk concerns. SAFETY: Generally well-tolerated based on traditional Brazilian use; modern clinical safety data limited. Best positioned as: (a) MILD DEPRESSION adjunct via dopamine mechanism (emerging — pending NCT02532660 results; preclinical-supported), (b) FATIGUE adjunct (traditional use + preclinical antifatigue evidence), (c) MEN'S SEXUAL DYSFUNCTION adjunct (extensive traditional use + preclinical PDE5/NO mechanism evidence; ED-specific human trials lacking), (d) MEMORY/COGNITION adjunct (anticholinesterase + antioxidant mechanisms; human evidence limited), (e) NOT recommended for SEVERE depression (limited human evidence; consult psychiatrist), (f) PREGNANCY: AVOID, (g) BLEEDING disorders: AVOID, (h) ANTIDEPRESSANT MEDICATIONS: CAUTION (theoretical serotonergic + dopaminergic additive effects), (i) SPECIES VERIFICATION CRITICAL — choose Trichilia catigua specifically, avoid generic 'catuaba' due to adulteration risk. Honest framing: Catuaba (Trichilia catigua) has SOLID PRECLINICAL EVIDENCE (Campos 2005 dopamine-mediated antidepressant mechanism + multiple preclinical studies) but LIMITED HUMAN CLINICAL TRIALS. NCT02532660 emerging Brazilian depression trial represents important transition to clinical evidence. Dopamine-focused mechanism is biochemically distinct from typical SSRI antidepressants — supports unique application for depression with anhedonia/motivation deficits. Extensive Brazilian traditional use base supports general safety + multi-indication applications. ADULTERATION RISK is significant practical concern — multiple species sold as 'catuaba' with controversial effects; verify Trichilia catigua specifically. Reasonable mild mood/fatigue/sexual function adjunct for those wanting traditional Brazilian botanical with dopamine-supportive mechanism — but human clinical evidence remains limited compared to dedicated antidepressants or branded botanical extracts.